Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 22 of 23, showing 5 Applications out of 112 total, starting on record 106, ending on 110

# Protocol No Study Title Investigator(s) & Site(s)

106.

ECCT/19/03/05   EPI-MAL-003 (Siaya)
    A prospective study to evaluate the safety, effectiveness and impact of the RTS,S/AS01E vaccine in young children in sub-Saharan Africa (v1.0 11Oct2017): Site-specific protocol for Siaya County, western Kenya   
Principal Investigator(s)
1. Simon Kariuki
2. Martina Oneko
Site(s) in Kenya
1. Bondo sub-county (Siaya county)
2. Gem sub-county (Siaya county)
 
View

107.

ECCT/22/03/07   ELEVATUM
    A PHASE IIIB/IV, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE FARICIMAB (RO6867461) TREATMENT RESPONSE IN TREATMENT-NAÏVE, UNDERREPRESENTED PATIENTS WITH DIABETIC MACULAR EDEMA   
Principal Investigator(s)
1. Dr. Oscar Muwale Onyango
2. Dr. Muchai Gachago
Site(s) in Kenya
1. The Nairobi Hospital (Nairobi City county)
2. City Eye Hospital (Nairobi City county)
 
View

108.

ECCT/23/02/03   INTREPiD
    Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy with High-Sensitivity Diagnostics (INTREPiD).   
Principal Investigator(s)
1. Steve M Taylor
2. Jeremiah K Laktabai
Site(s) in Kenya
Bungoma County
 
View

109.

ECCT/19/06/03   Evaluation of the RTS,S vaccine implementation in Kenya (MVPE)
      An evaluation of the cluster-randomised pilot implementation of the RTS,S/AS01 malaria vaccine through routine health systems in western Kenya         
Principal Investigator(s)
1. Aaron Samuels Samuels
Site(s) in Kenya
1. Bungoma County (Bung\'oma county)
2. Busia County (Busia county)
3. Homa Bay (Homa Bay county)
4. Kakamega County (Kakamega county)
5. Kisumu County (Kisumu county)
6. Migori County (Migori county)
7. Siaya County (Siaya county)
8. Vihiga County (Vihiga county)
 
View

110.

ECCT/22/05/02   BREATHER Plus
        A randomised open-label 2-arm, 96-week trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily dolutegravir/tenofovir-based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years of age in sub-Saharan Africa   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
Moi University Clinical Research Centre
 
View